-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction
(2849) Views (473) Full article downloads
Authors: James G McMurray, Robert A Feldman, Stephen M Auerbach, Herb DeRiesthal, Neal Wilson et al
Published Date January 2007
Volume 2007:3(6) Pages 975 - 981
DOI: http://dx.doi.org/10.2147/TCRM.S
James G McMurray1, Robert A Feldman2, Stephen M Auerbach3, Herb DeRiesthal4 Neal Wilson5, On behalf of the Multicenter Study Group6
1Medical Affiliated Research Center, Huntsville, AL, USA; 2Connecticut Clinical Research Center, Waterbury, CT, USA; 3California Professional Research, Newport Beach, CA, USA; 4Pfizer Inc, New York, NY, USA; 5Formerly Pfizer Global Research and Development, Sandwich, UK, currently PPD Inc, Cambridge, UK; 6Members of the multicenter study group are listed in the appendix.
Abstract: Because sildenafil citrate is a treatment, not a cure, for erectile dysfunction (ED), many men may choose to use it for an extended period. Men with ED who had previously completed 1 of 4 double-blind trials with short-term open-label extension (combined duration, 0.9–1.2 years) were eligible for this 4-year, open-label, extension study, which assessed the safety and effectiveness of flexible doses (25, 50, and 100 mg sildenafil) used as needed. Adverse events that were serious or led to dosing changes or discontinuation (temporary or permanent) were recorded. Many of the 979 participants (mean age, 58 [range, 27–82] years; mean ED duration, 4.5 years) had concomitant hypertension (28%), diabetes (22%), or hyperlipidemia (14%). Overall, 37 (3.8%) had treatment-related adverse events (none serious) requiring dosage change or discontinuation and 62 (6.3%) discontinued because of insufficient response. At each yearly assessment, more than 94% of participants responded affirmatively to the questions: “Are you satisfied with the effect of treatment on your erections?” and “If yes, has treatment improved your ability to engage in sexual activity?” These results argue against the loss of tolerability or the development of tachyphylaxis over a prolonged period of as needed, flexible-dose sildenafil treatment of men with ED.
Keywords: sildenafil citrate, erectile dysfunction, tolerability, effectiveness
Readers of this article also read:
Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
ABO and rhesus blood group distribution in Kurds
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Wearing facemasks when performing lumbar punctures: a snapshot of current practice amongst trainee doctors
Corrigendum
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




